470 related articles for article (PubMed ID: 30318516)
1. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours.
Maity A; Mick R; Huang AC; George SM; Farwell MD; Lukens JN; Berman AT; Mitchell TC; Bauml J; Schuchter LM; O'Hara M; Lin LL; Demichele A; Christodouleas JP; Haas NB; Patsch DM; Hahn SM; Minn AJ; Wherry EJ; Vonderheide RH
Br J Cancer; 2018 Nov; 119(10):1200-1207. PubMed ID: 30318516
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Goldberg SB; Gettinger SN; Mahajan A; Chiang AC; Herbst RS; Sznol M; Tsiouris AJ; Cohen J; Vortmeyer A; Jilaveanu L; Yu J; Hegde U; Speaker S; Madura M; Ralabate A; Rivera A; Rowen E; Gerrish H; Yao X; Chiang V; Kluger HM
Lancet Oncol; 2016 Jul; 17(7):976-983. PubMed ID: 27267608
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
Kluger HM; Chiang V; Mahajan A; Zito CR; Sznol M; Tran T; Weiss SA; Cohen JV; Yu J; Hegde U; Perrotti E; Anderson G; Ralabate A; Kluger Y; Wei W; Goldberg SB; Jilaveanu LB
J Clin Oncol; 2019 Jan; 37(1):52-60. PubMed ID: 30407895
[TBL] [Abstract][Full Text] [Related]
4. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
[TBL] [Abstract][Full Text] [Related]
5. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
Robert C; Ribas A; Hamid O; Daud A; Wolchok JD; Joshua AM; Hwu WJ; Weber JS; Gangadhar TC; Joseph RW; Dronca R; Patnaik A; Zarour H; Kefford R; Hersey P; Zhang J; Anderson J; Diede SJ; Ebbinghaus S; Hodi FS
J Clin Oncol; 2018 Jun; 36(17):1668-1674. PubMed ID: 29283791
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
[TBL] [Abstract][Full Text] [Related]
7. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial.
Welsh J; Menon H; Chen D; Verma V; Tang C; Altan M; Hess K; de Groot P; Nguyen QN; Varghese R; Comeaux NI; Simon G; Skoulidis F; Chang JY; Papdimitrakopoulou V; Lin SH; Heymach JV
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33051340
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.
Kothapalli A; Khattak MA
Melanoma Res; 2018 Apr; 28(2):155-158. PubMed ID: 29406396
[TBL] [Abstract][Full Text] [Related]
10. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.
Tumeh PC; Hellmann MD; Hamid O; Tsai KK; Loo KL; Gubens MA; Rosenblum M; Harview CL; Taube JM; Handley N; Khurana N; Nosrati A; Krummel MF; Tucker A; Sosa EV; Sanchez PJ; Banayan N; Osorio JC; Nguyen-Kim DL; Chang J; Shintaku IP; Boasberg PD; Taylor EJ; Munster PN; Algazi AP; Chmielowski B; Dummer R; Grogan TR; Elashoff D; Hwang J; Goldinger SM; Garon EB; Pierce RH; Daud A
Cancer Immunol Res; 2017 May; 5(5):417-424. PubMed ID: 28411193
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
[TBL] [Abstract][Full Text] [Related]
12. A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Qin A; Rengan R; Lee S; Santana-Davila R; Goulart BHL; Martins R; Baik C; Kalemkerian GP; Hassan KA; Schneider BJ; Hayman JA; Jolly S; Hearn J; Lawrence TS; Towlerton AMH; Tewari M; Thomas D; Zhao L; Brown N; Frankel TL; Warren EH; Ramnath N
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):170-177. PubMed ID: 31756415
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.
Razak AR; Cleary JM; Moreno V; Boyer M; Calvo Aller E; Edenfield W; Tie J; Harvey RD; Rutten A; Shah MA; Olszanski AJ; Jäger D; Lakhani N; Ryan DP; Rasmussen E; Juan G; Wong H; Soman N; Smit MD; Nagorsen D; Papadopoulos KP
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33046621
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
Imai H; Wasamoto S; Yamaguchi O; Suzuki K; Sugiyama T; Uchino J; Minemura H; Osaki T; Ishii H; Umeda Y; Mori K; Kotake M; Kagamu H; Morozumi N; Taniguchi H; Kasai T; Minato K; Kaira K
J Cancer Res Clin Oncol; 2020 Feb; 146(2):457-466. PubMed ID: 31853661
[TBL] [Abstract][Full Text] [Related]
15. The use of pembrolizumab for the treatment of metastatic uveal melanoma.
Kottschade LA; McWilliams RR; Markovic SN; Block MS; Villasboas Bisneto J; Pham AQ; Esplin BL; Dronca RS
Melanoma Res; 2016 Jun; 26(3):300-3. PubMed ID: 26848796
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Herbst RS; Baas P; Kim DW; Felip E; Pérez-Gracia JL; Han JY; Molina J; Kim JH; Arvis CD; Ahn MJ; Majem M; Fidler MJ; de Castro G; Garrido M; Lubiniecki GM; Shentu Y; Im E; Dolled-Filhart M; Garon EB
Lancet; 2016 Apr; 387(10027):1540-1550. PubMed ID: 26712084
[TBL] [Abstract][Full Text] [Related]
18. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
Peters S; Kerr KM; Stahel R
Cancer Treat Rev; 2018 Jan; 62():39-49. PubMed ID: 29156447
[TBL] [Abstract][Full Text] [Related]
19. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
